The pharmacokinetics of ciprofloxacin following single oral doses of 500 and 750 mg in 32 patients with various degrees of renal function impairment were investigated in an open, randomized crossover fashion.
Ciprofloxacin (Bay o 9867) is a new quinolone carboxylic acid derivative with broad antibacterial activity against gram-positive and gram-negative bacteria, including those resistant to aminoglycosides and P-lactam antibiotics (1, 12) .
Single-and multiple-oral-dose pharmacokinetic studies have shown that ciprofloxacin is rapidly absorbed and penetrates well into tissue (3, 5) . Ciprofloxacin is eliminated from serum by renal excretion and by extrarenal routes (11) . The purpose of this study was to investigate the pharmacokinetics of ciprofloxacin following single oral doses of 500 and 750 mg in patients with various degrees of renal function.
MATERIALS AND METHODS
Volunteers. Thirty-eight male patients with no known allergies to quinolone derivatives were enrolled in this study after written informed consent was obtained. Six of these subjects were subsequently excluded from analysis from both phases of the study (one vomited shortly after drug administration, one could not be assigned to a group because he had contradictory creatinine clearance [CLcRI values, two had received magnesium hydroxide before drug administration, one received Metamucil, and one ingested food before drug administration). Of the remaining 32 subjects, 4 (2 in each dosing group) were included in analysis in only one phase of the study because they had received magnesium hydroxide on one study day.
The renal function was estimated by CLCR determinations, with two 12-h urinary creatinine collections and two determinations of creatinine in serum prior to Cp(t) = Ae-at + Be-t + Ce -kat where Cp(t) (in micrograms per milliliter) is the concentra- Statistical analysis. The Wilcoxon rank sum test was used to compare pharmacokinetic parameters between the two groups of patients. The paired t tests was used to test changes in laboratory values.
RESULTS
In both groups 1 and 2, there were excellent correlations between HPLC values and bioassay values for serum (group 1: r = 0.959, y = 0.15 + 0.85x, P < 0.001; and group 2: r = 0.94, y = 0.125 + 0.95x, P < 0.001). Measurement of bias by comparing values from bioassay with those from HPLC revealed a mean difference of only 2.7% for samples in group 1 (310 paired observations) and 2.9o for samples in group 2 (271 paired observations). The correlation of values was not as good for urine (r = 0.610, y = 29 + 0.59x, P < 0.001; mean difference, 19.3%), with bioassay values being higher, probably owing to excretion of biologically active metabolites. These results were consistent with findings of previous studies (9) . Therefore, we used bioassay results for serum and HPLC results for urine in our analyses.
Mean concentrations of ciprofloxacin in serum after 500-and 750-mg doses had been given to patients in groups 1 and 2 are shown in Fig. 1 . In both groups, the 750-mg dose led to higher levels of ciprofloxacin in serum, higher C,,., longer Tma,,, and higher AUCo_ than the 500-mg dose (Table 2) .
Other parameters such as tj12, CLt.t, CLR, and CLNR were dose independent.
Patients in group 2 (those with impaired renal function) had higher dose concentrations in serum than those in group 1 (those with normal or slightly impaired renal function) after both doses. Compared with group 1, group 2 patients also had higher mean values for Cma, and longer Tmax (Table 2) . (NS)C (P < 0.01) (NS) (NS) (P < 0.01) (P < 0.01) (P < 0.01) (P < 0.01) ( The cumulative percentage of ciprofloxacin excreted and unchanged in the urine is shown in Fig. 2 . While the percentage of excretion in urine was dose independent, it was only 15% of the dose administered to group 2 patients compared with 26% for group 1 patients. Concentrations in urine after administration of 500 mg of ciprofloxacin are shown in Fig. 3 . Renal clearance of ciprofloxacin as a function of endogenous CLCR is shown in Fig. 4 . The correlation coefficient (r = 0.890) was highly significant (P < 0.001).
Ciprofloxacin was well tolerated by nearly all subjects. Four patients in the group given 500 mg and three in the group given 750 mg complained of side effects including headache, dizziness, nausea, vomiting, and diarrhea. Two of the patients experienced severe headache and diarrhea, while the remaining side effects were only of mild intensity, with no differences between groups 1 and 2. No significant Assuming that the bioavailability of ciprofloxacin was the same in both groups, the total ciprofloxacin clearance was greatly reduced in group 2 patients, primarily owing to the lower CLR. However, CLNR was also significantly reduced in group 2 patients. This may be because the patients in this group were older, often bedridden, and in generally poor physical condition. Reduced CLR in group 2 patients resulted in a 50% reduction in excretion of unchanged ciprofloxacin in urine. However, the 24-h ciprofloxacin concentration in urine for this group (Fig. 4) (11) , confirms the importance of extrarenal elimination routes for ciprofloxacin. Therefore, further dose reduction should probably be considered for patients with both impaired renal and impaired hepatic function.
